Immunologic profiles of multiple sclerosis treatments reveal shared early B cell alterations.

ABSTRACT:

Objective

We undertook a systems immunology approach of the adaptive immune system in multiple sclerosis (MS), overcoming tradeoffs between scale and level of detail, in order to identify the immunologic signature of MS and the changes wrought by current immunomodulatory treatments.

Methods

We developed a comprehensive flow cytometry platform measuring 38 immunologic cell types in the peripheral blood of 245 individuals in a routine clinical setting. These include patients with MS, untreated or receiving any of 4 current immunomodulatory treatments (interferon-β, glatiramer acetate, natalizumab, or fingolimod), patients with autoimmune thyroid disease, and healthy controls.

Results

An increase in memory CD8(+) T cells and B cells was observed in untreated patients wit

SUBMITTER: Dooley J 

PROVIDER: S-EPMC4872020 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature